Canadian Hepa B Treatment Program

The Canadian government has unveiled a health program that benefits individuals suffering from chronic hepatitis b. According to Canada's British Columbian government, there are around 300,000 to 600,000 individuals living with such condition and such numbers continue to rise and that Asian Pacific Islanders covers the highest percentage of the pie.

The provincial governmetn supports two drug treatment programs namely adefovir (marketed under the Brand name Hepsera) and entecavir (marketed as Baraclude). The estimated budget allocation is around $3 Million annually.

Each treatment program has corresponding treatment guide and each drug has its own program that deals with any incidence of virus drug resistance. The Vancouver Sun has more.